Most lung nodules smaller than 8 mm don’t need a biopsy and are safely monitored with follow-up CT scans. Once a solid nodule reaches 8 mm or larger, the risk of cancer rises enough that doctors shift from watching to acting, which may include a PET scan, a biopsy, or both. The exact decision depends on the nodule’s size, appearance, growth rate, and your personal risk factors.
The 8 mm Threshold for Solid Nodules
International guidelines converge on 8 mm as the dividing line between passive monitoring and active investigation for solid lung nodules found incidentally on CT scans. Below that size, periodic imaging is the standard approach. Above it, the options expand to include a repeat CT in three months, a PET scan to check metabolic activity, or tissue sampling.
At 10 mm and above, biopsy or further workup for a definitive diagnosis is generally recommended regardless of risk factors. Between 6 mm and 10 mm, the follow-up schedule depends on smoking history. Smokers typically get scanned at 3, 6, 12, 18, and 24 months, while nonsmokers follow a less frequent schedule at 6, 12, and 24 months. In either group, if the nodule grows by 2 mm or more in maximum diameter at any point, a definitive diagnosis is pursued.
Part-Solid and Ground-Glass Nodules
Not all lung nodules are solid white spots on a CT scan. Some appear hazy, like frosted glass, and others are a mix of solid and hazy tissue. These “subsolid” nodules follow different rules because they tend to grow more slowly, but some still represent early-stage cancers.
For part-solid nodules (a mix of solid and ground-glass), biopsy or surgical evaluation is recommended when the total size exceeds 15 mm. If the total size is under 15 mm but the solid portion measures 8 mm or more, a definitive diagnosis is still pursued. When the solid component is smaller than 8 mm, follow-up imaging is usually sufficient.
Pure ground-glass nodules, those with no solid component at all, are handled more conservatively. Biopsy or surgery is indicated when they exceed 15 mm, even if they haven’t changed. For those between 10 and 15 mm, an early follow-up scan at three months helps confirm persistence, and biopsy may follow if the nodule remains. Smaller ground-glass nodules (5 to 10 mm) only warrant biopsy if they grow or develop a solid component during surveillance, which can extend out to five years of periodic scans.
How Growth Rate Guides the Decision
Growth is one of the strongest signals that a nodule may be cancerous, and doctors measure it using something called volume doubling time: how long it takes the nodule to double in volume. Doubling times are grouped into three tiers of suspicion. A doubling time over 600 days is the least concerning, 400 to 600 days is intermediate, and under 400 days raises the highest suspicion for malignancy.
In screening studies, malignant solid nodules had an average doubling time of about 204 days, while benign nodules averaged 386 days. Roughly 92% of malignant nodules doubled in under 400 days. The catch is that 58% of growing benign nodules also fell into that same fast-growing range, which is why growth alone doesn’t confirm cancer. It does, however, push the decision firmly toward biopsy. Any solid nodule that grows by 2 mm or more on follow-up imaging is a candidate for tissue sampling, regardless of its original size.
What PET Scans Add to the Picture
For nodules 8 mm and larger, a PET scan can help estimate whether a nodule is metabolically active, which is a hallmark of cancer cells. The scan produces a value called SUVmax that reflects how aggressively tissue absorbs a glucose-like tracer. More than 90% of nodules with an SUVmax below 2.0 turn out to be benign. An SUVmax of 2.5 is commonly used as a cutoff, yielding roughly 93% sensitivity for detecting cancer. At an SUVmax of 4 or higher, the distinction between benign and malignant disease is sharpest, with about 84 to 85% sensitivity and specificity.
A strongly positive PET scan (described as “intensely hypermetabolic”) is considered an indication for surgery in American College of Chest Physicians guidelines. A negative PET result is reassuring but doesn’t rule out cancer entirely, particularly for slow-growing nodules or ground-glass lesions that may not take up the tracer well. PET scans also have higher false-positive rates in regions where infections like tuberculosis are common, since inflammatory tissue lights up too.
How the Biopsy Is Done
Where the nodule sits in your lung determines which biopsy method works best. The two main approaches are a needle biopsy guided by CT imaging and a bronchoscopic biopsy using ultrasound.
CT-guided needle biopsy works well for nodules in the outer portions of the lung, close to the chest wall, and away from major blood vessels. The needle passes through the skin and chest wall directly into the nodule. Nodules located deeper in the lung, near the center of the chest, or close to large blood vessels are better reached through the airways using bronchoscopic ultrasound. This technique threads a small probe through your airway to reach the nodule from the inside.
For the bronchoscopic approach, diagnostic accuracy improves with larger nodules and those located closer to the airway branches near the center of the lung. For CT-guided needle biopsy, nodules closer to the chest wall are easier to reach and carry a lower complication risk.
Biopsy Risks to Understand
The most common complication of CT-guided lung biopsy is a pneumothorax, where air leaks into the space around the lung and partially collapses it. A large systematic review found an overall pneumothorax rate of about 25.9%, though the range across studies was wide (4 to 52%). Most of these are small air leaks that resolve on their own or with brief observation. Only about 6.9% of all biopsies required a chest tube to drain the air. The risk of pneumothorax increases when the nodule is farther from the chest wall, since the needle must travel through more lung tissue. Nodules near large blood vessels carry a small additional risk of bleeding.
These complication rates are why doctors don’t biopsy every nodule. For small, low-risk nodules, the chance that biopsy causes harm outweighs the small probability of cancer. The decision to biopsy represents a judgment that the likelihood of malignancy is high enough to justify the procedural risk.
Risk Factors That Lower the Threshold
Your personal cancer risk influences how aggressively a nodule is investigated. Factors that push doctors toward earlier biopsy include a history of smoking, older age, a family history of lung cancer, prior exposure to asbestos or radon, and a personal history of any cancer. A nodule with irregular or spiculated edges on CT, or one located in an upper lobe, also raises suspicion.
People who are immunosuppressed or have a history of another malignancy present a particular challenge. In these patients, lung nodules may represent a new primary cancer, a metastasis from a known cancer, or an infection taking advantage of a weakened immune system. The range of possibilities is broader, and the urgency of diagnosis is often higher. Biopsy is pursued more aggressively in these situations, though getting a clear answer can be harder. In one study of immunocompromised patients, open surgical biopsy yielded a specific diagnosis 81% of the time, while bronchoscopic biopsy succeeded only 32% of the time.
The Typical Decision Pathway
In practice, the process unfolds in stages. A nodule is spotted on a CT scan, often incidentally during imaging for something else. If it’s under 6 mm and you have no major risk factors, it may not need any follow-up at all. Between 6 and 8 mm, you’ll likely get a series of follow-up CTs over one to two years. At 8 mm or above, a PET scan is often the next step. If the PET is positive or the nodule has suspicious features, biopsy follows. If a nodule of any size grows by 2 mm or more on follow-up imaging, or if a ground-glass nodule develops a new solid component, the pathway accelerates toward tissue diagnosis.
The overall goal is straightforward: catch cancers early enough to cure them while sparing the majority of people with benign nodules from unnecessary procedures. Since roughly 95% of lung nodules found on screening CT scans are not cancer, the tiered approach of watching small nodules and acting on larger or growing ones strikes that balance.